Site Editor

David S. Ettinger, MD, FACP, FCCP

Advertisement
Advertisement

Shorter Duration of Treatment With Nivolumab Plus Ipilimumab in Advanced NSCLC

By: Justine Landin, PhD
Posted: Friday, October 14, 2022

Nivolumab plus ipilimumab treatment for 6 months may be as efficacious as the standard 2 years of immunotherapy for patients with advanced non–small cell lung cancer (NSCLC), according to the results of the IFCT-1701 multicenter noninferiority randomized phase III trial. Although these findings are premature because of trial discontinuation, there was no significant difference in progression-free survival for those who received combination immunotherapy for 6 months and subsequent chemotherapy compared with combination immunotherapy alone. These study results were presented by Gerard Zalcman, MD, of Université Paris Cité, and colleagues during the European Society for Medical Oncology (ESMO) Congress 2022 (Abstract 972O).

“The nonsignificant progression-free survival difference between the 6 months and the continuation arms is hypothesis-generating, since data are underpowered due to trial premature halt,” stated the investigators.

Treatment-naive patients with stage IV NSCLC and measurable disease were enrolled in the trial (n = 265). Patients received nivolumab every 2 weeks (3 mg/kg) plus ipilimumab every 6 weeks (1 mg/kg) for a total of 6 months or until disease progression or toxicity. At the time of presentation, surviving patients with disease control and without significant treatment-related adverse events (n = 71) were randomly assigned to arm A (continuation of therapy) or arm B (observation). Patients in arm A received second-line platinum-based chemotherapy, and those in arm B resumed the immunotherapy combination.

At the median follow-up of 21 months, median progression-free survival was 20.8 months with treatment continuation and was not reached with observation. Progression-free survival at 12 months was 57.1% with treatment continuation and 77.6% with observation (P = .09). There was no significant difference between the arms in terms of overall survival (although data were immature) or grade 3 to 5 treatment-related adverse events.

Disclosure: For full disclosures of the study authors, visit cslide.ctimeetingtech.com.


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.